Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma
BackgroundLung squamous cell carcinoma (LUSC) generally correlates with poor clinical prognoses due to the lack of available prognostic biomarkers. This study is designed to identify a potential biomarker significant for the prognosis and treatment of LUSC, so as to provide a scientific basis for cl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.756096/full |
| _version_ | 1818580244117848064 |
|---|---|
| author | Cailian Wang Xuyu Gu Xiuxiu Zhang Min Zhou Yan Chen |
| author_facet | Cailian Wang Xuyu Gu Xiuxiu Zhang Min Zhou Yan Chen |
| author_sort | Cailian Wang |
| collection | DOAJ |
| description | BackgroundLung squamous cell carcinoma (LUSC) generally correlates with poor clinical prognoses due to the lack of available prognostic biomarkers. This study is designed to identify a potential biomarker significant for the prognosis and treatment of LUSC, so as to provide a scientific basis for clinical treatment decisions.MethodsGenomic changes in LUSC samples before and after radiation were firstly discussed to identify E2 factor (E2F) pathway of prognostic significance. A series of bioinformatics analyses and statistical methods were combined to construct a robust E2F-related prognostic gene signature. Furthermore, a decision tree and a nomogram were established according to the gene signature and multiple clinicopathological characteristics to improve risk stratification and quantify risk assessment for individual patients.ResultsIn our investigated cohorts, the E2F-related gene signature we identified was capable of predicting clinical outcomes and therapeutic responses in LUSC patients, besides, discriminative to identify high-risk patients. Survival analysis suggested that the gene signature was independently prognostic for adverse overall survival of LUSC patients. The decision tree identified the strong discriminative performance of the gene signature in risk stractification for overall survival while the nomogram demonstrated a high accuracy.ConclusionThe E2F-related gene signature may help distinguish high-risk patients so as to formulate personalized treatment strategy in LUSC patients. |
| first_indexed | 2024-12-16T07:14:31Z |
| format | Article |
| id | doaj.art-05a85628b38a4202b99288909268a4b8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T07:14:31Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-05a85628b38a4202b99288909268a4b82022-12-21T22:39:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.756096756096Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell CarcinomaCailian Wang0Xuyu Gu1Xiuxiu Zhang2Min Zhou3Yan Chen4Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, ChinaDepartment of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, ChinaBackgroundLung squamous cell carcinoma (LUSC) generally correlates with poor clinical prognoses due to the lack of available prognostic biomarkers. This study is designed to identify a potential biomarker significant for the prognosis and treatment of LUSC, so as to provide a scientific basis for clinical treatment decisions.MethodsGenomic changes in LUSC samples before and after radiation were firstly discussed to identify E2 factor (E2F) pathway of prognostic significance. A series of bioinformatics analyses and statistical methods were combined to construct a robust E2F-related prognostic gene signature. Furthermore, a decision tree and a nomogram were established according to the gene signature and multiple clinicopathological characteristics to improve risk stratification and quantify risk assessment for individual patients.ResultsIn our investigated cohorts, the E2F-related gene signature we identified was capable of predicting clinical outcomes and therapeutic responses in LUSC patients, besides, discriminative to identify high-risk patients. Survival analysis suggested that the gene signature was independently prognostic for adverse overall survival of LUSC patients. The decision tree identified the strong discriminative performance of the gene signature in risk stractification for overall survival while the nomogram demonstrated a high accuracy.ConclusionThe E2F-related gene signature may help distinguish high-risk patients so as to formulate personalized treatment strategy in LUSC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.756096/fullLUSCE2F pathwaygene signatureprognosisrisk score |
| spellingShingle | Cailian Wang Xuyu Gu Xiuxiu Zhang Min Zhou Yan Chen Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma Frontiers in Oncology LUSC E2F pathway gene signature prognosis risk score |
| title | Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma |
| title_full | Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma |
| title_fullStr | Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma |
| title_full_unstemmed | Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma |
| title_short | Development and Validation of an E2F-Related Gene Signature to Predict Prognosis of Patients With Lung Squamous Cell Carcinoma |
| title_sort | development and validation of an e2f related gene signature to predict prognosis of patients with lung squamous cell carcinoma |
| topic | LUSC E2F pathway gene signature prognosis risk score |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.756096/full |
| work_keys_str_mv | AT cailianwang developmentandvalidationofane2frelatedgenesignaturetopredictprognosisofpatientswithlungsquamouscellcarcinoma AT xuyugu developmentandvalidationofane2frelatedgenesignaturetopredictprognosisofpatientswithlungsquamouscellcarcinoma AT xiuxiuzhang developmentandvalidationofane2frelatedgenesignaturetopredictprognosisofpatientswithlungsquamouscellcarcinoma AT minzhou developmentandvalidationofane2frelatedgenesignaturetopredictprognosisofpatientswithlungsquamouscellcarcinoma AT yanchen developmentandvalidationofane2frelatedgenesignaturetopredictprognosisofpatientswithlungsquamouscellcarcinoma |